Bio­gen's $7.3B M&A deal, lay­offs; R&D shake­up at Pfiz­er, As­traZeneca; Scal­ing rare dis­ease meds; Q2 earn­ings; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points news­room is con­tin­u­ing to grow! Rey­nald Cas­tañe­da joined us this week from Lon­don — he will lead two oth­er UK col­leagues, Ay­isha Shar­ma and An­na Brown, in beef­ing up our ear­ly morn­ing re­port­ing. On the US side, Ly­dia Ram­sey Pflanz­er will be spear­head­ing the ex­pan­sion of our cov­er­age in­to health tech. If you missed it, read Drew Arm­strong’s note for more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER